Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases. The ACRS news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates, and investor events drawn from press releases and regulatory disclosures.
Recent Aclaris news has focused on its immunology pipeline, including ATI-2138, a potent and selective oral ITK/JAK3 inhibitor, and its antibody franchise targeting TSLP and IL-4/IL-13 pathways. The company has reported positive Phase 2a results for ATI-2138 in moderate-to-severe atopic dermatitis, initiation and progress of a Phase 2 trial of its anti-TSLP monoclonal antibody bosakitug (ATI-045) in atopic dermatitis, and Phase 1a and Phase 1b development of its bispecific anti-TSLP/IL-4Rα antibody ATI-052, including a Phase 1b proof-of-concept trial in atopic dermatitis.
Investors and followers of ACRS can use this news feed to track key milestones such as interim and top line clinical results, updates on additional indications for ATI-2138, and timelines for proof-of-concept and later-stage trials. The page also captures corporate developments, including quarterly and year-to-date financial results, cash runway commentary, index inclusions such as the Nasdaq Biotechnology Index, and participation in healthcare and biotechnology conferences and R&D Day events.
By reviewing the ACRS news page regularly, readers can follow how Aclaris communicates progress across its oral kinase inhibitor and biologics franchises, how it describes the evolution of its multi-stage portfolio, and how financial and strategic updates align with its stated focus on patients with immuno-inflammatory diseases who lack satisfactory treatment options.
Aclaris Therapeutics (NASDAQ: ACRS) has initiated a randomized (3:1), blinded, placebo-controlled Phase 1b proof-of-concept trial in atopic dermatitis (AD) for ATI-052, a bispecific anti-TSLP/IL-4Rα antibody. The company cited positive Phase 1a interim results showing a strong safety and tolerability profile, extended pharmacokinetics, and concentration-dependent pharmacodynamics at low dose. The Phase 1b AD trial will assess safety, EASI, IGA response, PP-NRS, PK, and PD using lesional and non-lesional skin tape strips. Aclaris expects to start a second Phase 1b POC trial in asthma in Q1 2026 and to report topline results from both POC trials in H2 2026.
Aclaris Therapeutics (NASDAQ: ACRS) reported positive interim Phase 1a SAD/MAD results for its anti-TSLP/IL-4Rα bispecific antibody ATI-052 on January 6, 2026. The randomized, blinded, placebo-controlled study in healthy adults tested single doses (30, 120, 360, 720 mg) and multiple doses (240, 480 mg).
Key findings: favorable safety with no Grade 3 drug-related TEAEs or serious adverse events, predominant Grade 1 TEAEs, PK half-life ≥26 days, dose-proportional Cmax/AUC, and robust PD target inhibition including near-complete TSLP/IL-4 pathway suppression lasting ≥6 weeks at 360 mg. Company expects Phase 1b POC trials in AD and asthma in Q1 2026 and plans a Phase 2b AD trial in H2 2026.
Aclaris Therapeutics (NASDAQ: ACRS) was added to the Nasdaq Biotechnology Index (NBI), effective at the close of trading on December 19, 2025. The NBI tracks securities classified as biotechnology or pharmaceutical under the Industry Classification Benchmark and uses a modified capitalization-weighted methodology.
The company met NBI eligibility requirements, including minimum market capitalization, average daily trading volume and public company seasoning; the index is evaluated annually each December.
Aclaris Therapeutics (NASDAQ: ACRS) said CEO Dr. Neal Walker and senior leadership will join a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City.
The discussion is scheduled for Tuesday, December 2, 2025 at 11:00 AM EST. A live and archived webcast will be available on the company Events page at aclaristx.com and will remain accessible for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) reported Q3 2025 results and a corporate update highlighting clinical progress and financial position. The company posted positive Phase 2a topline and EADV presentation data for ITK/JAK3 inhibitor ATI-2138 (week 4 EASI -77%, BSA -64%, PP-NRS -45%) and plans a Phase 2 in an additional indication in H1 2026. Topline readouts for bispecific ATI-052 Phase 1a and anti-TSLP bosakitug Phase 2 are expected in early and H2 2026, respectively. Cash, cash equivalents and marketable securities were $167.2M as of Sept 30, 2025, with a runway into H2 2028. Q3 net loss widened to $14.6M.
Aclaris Therapeutics (NASDAQ: ACRS) will participate in three healthcare conferences in November 2025 with senior leadership presenting fireside chats.
Key events: Guggenheim on Nov 12, 2025 at 11:00 AM EST (Dr. Neal Walker et al.); Stifel on Nov 12, 2025 at 1:20 PM EST (Dr. Hugh Davis et al.); and Jefferies Global on Nov 17, 2025 at 2:00 PM GMT / 9:00 AM EST (Dr. Walker).
Live and archived webcasts will be available on the company Events page and accessible on the Aclaris website for at least 30 days.
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company, will host its 2025 R&D Day on October 14, 2025 in New York. The event will focus on the company's development of kinase and immune pathway inhibitor franchises for immuno-inflammatory diseases.
The presentation will feature insights from company leadership and expert speakers, including Dr. Zuzana Diamant and Dr. Michael C. Cameron. Key topics include the company's progress in developing small and large molecule candidates, their innovative discovery platform, ITK inhibition franchise, TSLP franchise development, and updates on ongoing clinical trials.
Aclaris Therapeutics (NASDAQ:ACRS) announced that additional data from its Phase 2a trial of ATI-2138 in atopic dermatitis will be presented as a late-breaking abstract at the 2025 EADV Congress in Paris. ATI-2138 is a selective oral covalent inhibitor targeting ITK and JAK3 for moderate-to-severe atopic dermatitis treatment.
The presentation, titled "Molecular and Clinical Effects of oral ATI-2138," will be delivered by Dr. Jessica Beaziz-Tordjman on September 18, 2025, at 14:15 CEST. The study's results will provide insights into the drug's effectiveness in treating moderate-to-severe atopic dermatitis patients.
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, has announced its participation in two major healthcare conferences in September 2025.
CEO Dr. Neal Walker and the senior leadership team will participate in a fireside chat at the Cantor Global Healthcare Conference on September 3 at 1:00 PM EDT. Additionally, Dr. Walker will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9 at 9:00 AM EDT. Both events will be webcast live and archived on the company's website.
Aclaris Therapeutics (NASDAQ:ACRS) reported Q2 2025 financial results and provided significant pipeline updates. The company achieved positive results in its Phase 2a trial of ATI-2138, their ITK/JAK3 inhibitor for atopic dermatitis, demonstrating strong efficacy and tolerability. Additionally, Aclaris initiated dosing in two key trials: a Phase 2 trial of bosakitug (anti-TSLP antibody) and a Phase 1a/1b program for ATI-052 (anti-TSLP/IL-4R bispecific antibody).
Financially, Aclaris reported a net loss of $15.4 million in Q2 2025, with cash reserves of $180.9 million as of June 30, 2025. The company expects its current cash position to fund operations into the second half of 2028. R&D expenses increased to $11.4 million, primarily due to expanded clinical development activities.
FAQ
What is the current stock price of Aclaris Therapeutics (ACRS)?
What is the market cap of Aclaris Therapeutics (ACRS)?
